Three years after the massacre at the Nova music festival site on October 7, 2023, a difficult question remains: what does it actually mean for a survivor to recover?
For Prof. Rachel Yehuda, a trauma researcher at the Icahn School of Medicine at Mount Sinai in New York City, simply helping a patient get through the week is valuable work. But it is a different task, she notes, from helping that person reach a point where trauma no longer dictates how they live.
The distinction carries particular weight at a moment when survivors are still living with the consequences of the attack, in conditions that make it hard to feel safe. It also matters when weighing new treatments whose promise can raise expectations long before clinicians understand whom they will help, under what circumstances, and for how long.
These questions shaped SafeHeart’s second annual conference, held last Wednesday (November 11) at the Peres Center for Peace and Innovation in Jaffa. Researchers, clinicians, survivors, and their families convened to discuss trauma, psychedelics, and the role of community in healing.
Yehuda urged particular caution about using psychedelics to treat festival survivors. For people who may have been under the influence when the massacre began, she suggested, another altered state of consciousness should not automatically become a first line of treatment.
The longing for relief is understandable, she explained, but an experience that offers escape and one that helps a person process trauma are not the same thing.
What is SafeHeart?
Founded as an emergency mental health initiative on October 7, 2023, SafeHeart has built its work around the specific needs of Nova survivors, including those who lived through extreme violence while under the influence of psychoactive substances. Understanding that experience is part of treating its aftermath; the treatment itself does not necessarily involve administering psychedelic drugs.
For Yehuda, who directs Mount Sinai’s Parsons Research Center for Psychedelic Healing, any conversation about psychedelic therapy must also address how therapists are trained, how patients are prepared, and how they are supported afterward. She argued that any Israeli approval framework for psychedelic medicines should account for the psychological care that accompanies their use, rather than focusing on the drugs alone.
“Supportive psychological care is an essential part of treatment with psychedelic drugs,” she said.
Training therapists and defining what appropriate care looks like, she contended, must happen before treatment patterns become entrenched.
Alongside these clinical questions, researchers presented findings aimed at explaining why some survivors continue to struggle, and whether those at higher risk could be identified sooner.
Research presented by University of Haifa professors Roee Admon and Roy Salomon forms part of a project following 1,268 survivors. Admon leads the university’s Stress and Psychopathology Research Lab, while Salomon also serves on SafeHeart’s board and directs its research.
The broader observational study tracks survivors from the weeks after the attack to roughly two years later, using a comparison group drawn from the Israeli trance music community. It combines questionnaires with biological measurements to chart how people fare over time.
One analysis presented at the conference found that survivors with higher levels of an inflammation-related protein, measured in saliva soon after the attack, tended to report more severe post-traumatic stress symptoms later. The association held even after researchers adjusted for how severe their symptoms had been at the outset.
The researchers cautioned that the finding is preliminary and has not yet been published. Any practical application lies in the future, they said: the results need to be replicated, and the underlying mechanism better understood.
A separate analysis looked at survivors’ use of psychoactive substances in the months after the attack.
Among 453 survivors surveyed eight to 12 months later, about 70% reported using more than one type of psychoactive substance, including alcohol.
What the researchers set out to examine was patterns of use and the reasons behind them. A further analysis used a language model to study survivors’ accounts of what they had taken, how they experienced it, and the effects they attributed to different substances.
Such accounts may help researchers frame better questions, but they cannot establish what a drug did to someone’s recovery. Participants chose what to take; researchers did not assign substances. An association between substance use and mental health cannot, by itself, reveal which one influenced the other.
For clinicians, understanding what patients are taking and why still belongs within the fuller picture of their lives. Seeking relief, seeking escape, and seeking treatment may overlap, but they are not interchangeable.
The scale of survivors’ ongoing distress came through clearly in findings presented by Prof. Yuval Neria, a professor of clinical medical psychology at Columbia University and director of trauma and PTSD at the New York State Psychiatric Institute.
In a study of 392 Nova survivors assessed twice during the first year after the attack, about 67% scored above a screening threshold for probable PTSD at one to five months. At eight to 12 months, about 65% remained above that threshold.
Examining individual symptom patterns showed that roughly 29% had persistently high symptoms and that in 26% symptoms worsened. Together, they made up about 55% of the group. About a quarter followed a course of relatively low symptoms, which researchers described as resilient, while a fifth partially improved.
These are first-year findings, not a measure of survivors’ condition three years on. They rest on symptom questionnaires rather than individual clinical diagnoses, yet they show why the passage of time cannot be assumed to bring steady improvement, and why the notion that “time heals all wounds” does not necessarily hold here.
Neria also spoke about the importance of childhood trauma and sleep in understanding patients’ vulnerability and treatment needs. In the same study, childhood adversity and poorer sleep after the attack were linked to lower odds of a resilient course. He urged clinicians to ask about sleep and to address difficulties early.
His presentation also examined distress rooted in guilt and a loss of trust. He described “moral injury” as lasting anguish following experiences that violate deeply held moral beliefs or expectations.
For Nova survivors, he explained, this can include guilt at being alive when friends were killed or taken hostage, anguish over being unable to help, and a sense of betrayal after waiting hours for rescue. Such guilt does not mean a survivor was responsible for what happened, but it can still shape how they understand their own survival and whether they feel able to trust others.
The practical implication for clinicians, he stressed, is to ask about guilt, shame, and anger alongside fear. Rebuilding a life after the attack may require repairing a sense of connection to other people, not only addressing memories of danger.
The attack itself is part of the clinical picture, but so are the conditions in which a person must live afterward.
Prof. Merav Roth, a clinical psychologist, psychoanalyst, and co-founder of First Line Med, which provides free long-term treatment for people affected by October 7, added another dimension to the discussion.
Across generations, she said, families can pass down resources for resilience as well as the effects of trauma.
The conference program gave those relationships considerable space. Sessions addressed parents’ support groups, the experience of mothers of survivors, and community-based approaches to care.
Continuity of care, commitment for years
SafeHeart’s services include individual therapy, group sessions, retreats, and support for relatives.
For Ronen Shalev, whose son Roei survived the festival but died by suicide in October 2025, the difficulty of recognizing distress was deeply personal.
Speaking at the conference, Shalev described the gap between what he could see from the outside and the suffering his son carried.
He spoke of not knowing which tools to ask for, and urged those working with survivors to seek out people who were struggling rather than wait for them to come forward.
His account underscored how much can remain hidden even from those closest to a survivor, and how vital it is that relatives, too, know where to turn for help.
SafeHeart CEO Efrat Atun said research should help make care more responsive to survivors’ needs while reinforcing the need to sustain it over time.
“It takes continuity of care and a commitment that lasts for years,” she said.
Three years after the attack, researchers are still probing why symptoms persist, how substance use fits into survivors’ lives, and whether biological markers can help flag those who need closer attention.
For families and clinicians, those questions sit alongside the daily work of supporting someone whose needs may keep changing.
Getting through the week can be a meaningful achievement. But Yehuda’s distinction keeps another goal in view: reaching a point where trauma remains part of a person’s life without continuing to govern it.
Also Read
- Anthropic Shares Slide as AI Sell-Off Deepens Despite Record IPO
- Service Industries Subsidiary Explores Acquisition of Pakistani Clothing Retail Chain
- Japan Secures 25% Boost in Large Bluefin Tuna Quota Starting 2027
- Driven by Poverty, Trapped by Traffickers: Niger’s Forced Beggar Rings Across West Africa

